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Objective: To compare a fixed combination of 0.03% bimatoprost and 0.5% timolol (BTFC) 
with latanoprost monotherapy (LM) in treatment-naïve patients with open-angle glaucoma 
(OAG) and risk factors for glaucomatous progression.
Methods: Patients were enrolled at 15 sites in Spain and Portugal, and were randomized 1:1 
to BTFC or LM. Patients instilled one drop of medication once per day at 8 pm for 12 weeks. 
The primary outcome was change in intraocular pressure (IOP) at 12 weeks.
Results: Of 81 patients enrolled, 43 were randomized to BTFC and 38 to LM. Mean (SD) change 
in IOP from baseline to 12 weeks was significantly greater for BTFC than for LM: −13.5 mmHg 
(4.48) versus −11.4 mmHg (3.19), respectively (P=0.003). Similarly, at 12 weeks, significantly 
more BTFC patients than LM patients had IOP reductions of $40% (74.4% versus 47.4%, 
P=0.015) or $50% (46.5% versus 15.8%, P=0.003). Adverse events were more frequent with 
BTFC than with LM (33 versus 13 events), but most were mild in severity. The only serious 
adverse event (colon cancer) was adjudged unrelated to the study medication.
Conclusion: BTFC was effective and well tolerated in treatment-naïve patients with OAG at 
high risk of progression.
Keywords: open-angle, fixed combinations
Introduction
European Glaucoma Society (EGS) guidelines on the treatment of primary open-angle 
glaucoma (POAG) recommend an individualized approach to management, setting 
a target intraocular pressure (IOP) on the basis of risk factors such as family history, 
IOP at presentation, visual field defects or the presence of pseudoexfoliation, with the 
goal of preventing significant visual disability in the patient’s lifetime.1 In particular, 
data from the Early Manifest Glaucoma Trial (EMGT) show that the more advanced 
the glaucoma is at presentation, with greater loss of visual field, the greater the long-
term risk of further glaucomatous progression.2 It therefore follows that in patients 
with advanced glaucoma, risk factors for glaucomatous progression and a reasonable 
life expectancy, early and aggressive initial IOP lowering may offer the best chance 
of preventing visual impairment.
While the EGS guidelines recommend that initial therapy for glaucoma is usu-
ally with a single agent,1 they also note that many patients require additional agents 
to reach their target IOP, and that in such cases, a fixed combination medication 
may offer advantages over concurrent therapy in terms of convenience, adherence, 
and tolerability.1 Prostaglandin analogs are now well established as the most effec-
tive monotherapies in terms of IOP lowering,3 and a meta-analysis suggests that 
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bimatoprost has a greater overall IOP-lowering effect than 
latanoprost or travoprost.4 Similarly, a recent meta-analysis 
suggested that a fixed combination of 0.03% bimatoprost and 
0.5% timolol (BTFC) was more effective at lowering IOP 
than either latanoprost/timolol or travoprost/timolol fixed 
combinations;5 no tafluprost/timolol fixed combination is 
currently available. BTFC therefore seems a rational choice 
for maximal IOP lowering in patients for whom this is the 
overriding therapeutic consideration.
This study investigated the use of BTFC compared with 
latanoprost monotherapy (LM) in treatment-naïve subjects 
with risk factors for glaucomatous progression. Our hypoth-
esis was that BTFC would result in better IOP control and 
quicker attainment of an individual target IOP than LM.
Methods
This was a Phase IV, randomized, multicenter, investi-
gator-masked study, registered with ClinicalTrials.gov 
(NCT012435676) and the EU Clinical Trials Register 
(2009-012799-28). Patients were eligible for inclusion 
if they fulfilled all of the following criteria: i) aged $18 
and #85 years (male or female); ii) diagnosed with open-
angle glaucoma (POAG or pseudoexfoliative glaucoma), with 
baseline IOP $27 mmHg and #34 mmHg in one or both 
eyes; iii) no previous ocular hypotensive medications; iv) at 
least one of the following risk factors for rapid progression: 
pseudoexfoliation, family history of glaucoma, pigment 
dispersion, optic disc hemorrhage, visual field mean devia-
tion worse than −6 dB, IOP $27 mmHg in both eyes; v) best 
corrected visual acuity (BCVA) of Snellen equivalent 20/60 
or better in each eye. To be included, patients also needed to 
give informed consent to participate in the study, and to have 
two reliable visual field tests: one performed within 6 months 
prior to baseline (day 0) visit and another at baseline prior 
to randomization.
Patients were excluded from participation if they had any 
of: i) a history of refractive surgery; ii) intraocular surgery 
within 3 months prior to baseline; iii) a visual field defect 
requiring medical intervention; iv) any contraindication 
to β-adrenoceptor antagonist therapy; v) any other known 
allergy or sensitivity to the study medications or their com-
ponents; vi) any ocular inflammation or infection within 
3 months prior to baseline, apart from mild blepharitis, 
or any history of uveitis; vii) any corneal abnormalities in 
either eye that would preclude accurate IOP readings with 
an applanation tonometer; viii) an ocular trauma in either 
eye within 6 months prior to baseline; ix) a requirement for 
chronic use during the study of ocular medications other 
than the study medications, in either eye; x) intermittent 
use of oral, injectable, or topical ophthalmic steroids within 
21 days prior to baseline, or anticipated use during the study; 
xi) any other condition or situation that might put the subject 
at significant risk, confound the study results, or significantly 
impede participation. Female patients who were pregnant, 
nursing, or planning a pregnancy, or who were of childbear-
ing potential and not using a reliable means of contraception, 
were also excluded.
This trial was conducted in accordance with the principles 
of GCP CPMP/ICH/135/95.7 All subjects gave informed 
consent to participate, and the study was approved by the 
University  Hospital Ramon y Cajal Ethics Committee for 
Clinical Research (Spain) and the National Ethics Committee 
for Clinical Investigation (Portugal). The randomization list and 
envelopes were generated by an independent statistician with 
no connection to the study. Prior to initiation of study treat-
ment, each subject qualifying for entry was assigned a unique 
randomization number sequentially at the recruitment site.
study protocol
Patients were enrolled at 15 sites in Spain (10 sites) and 
Portugal (5 sites) (see ‘Acknowledgments’ section for 
list), and were randomized 1:1 to either BTFC or LM. The 
fixed-combination formulation of bimatoprost and timolol 
means that the beta-blocker and the prostaglandin analog 
are combined into a single drop and therefore they cannot be 
separated. Patients were aware of their treatment allocation, 
but were instructed not to reveal it to assessing investigators. 
They were instructed to instill one drop of study medica-
tion in each eye requiring treatment, once a day at 8 pm, 
for 12 weeks. Evening dosing was used because 24-hour 
IOP monitoring suggests it may provide slightly better IOP 
control than morning dosing.8,9 Whilst BTFC can be admin-
istered in the morning or evening, evening dosing is usually 
recommended and matched the requirement for LM dosing. 
If both eyes were treated, the eye with the highest IOP was 
the study eye and was used for analysis; if both eyes had the 
same IOP, then the right eye was the study eye.
There were five scheduled visits: i) visit 0 (pre-study, 
day −14 to day 0), 2 weeks prior to baseline; ii) visit 1 (baseline, 
day 0), with IOP measurements at 8 am, 12 pm, and 4 pm; iii) 
visit 2 (week 2), with an IOP measurement at 8 am; iv) visit 3 
(week 6), with IOP measurements at 8 am, 12 pm, and 4 pm; 
v) visit 4 (week 12), with IOP measurements at 8 am, 12 pm, 
and 4 pm. The first dose of study medication was administered 
on the evening of the baseline visit (day 0), and the last dose 
on the evening prior to the last visit at week 12.
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study outcomes
The primary efficacy endpoint of the study was the change 
in IOP (mean of 8 am, 12 pm, and 4 pm measurements) from 
baseline to 12 weeks. The secondary efficacy endpoints were: 
i) specific changes in IOP at 8 am, 12 pm, and 4 pm from 
baseline to 12 weeks; ii) the percentages of patients reach-
ing predefined target pressure thresholds (ranging from 13 
to 18 mmHg) and reductions (of 20% to 50%) at 12 weeks; 
iii) the absolute difference between patients’ highest IOP at 
baseline and at 12 weeks; iv) the absolute difference between 
patients’ lowest IOP at baseline and at 12 weeks.
The safety endpoints were the incidence of adverse events 
(AEs) throughout the study, and BCVA, which was measured 
at baseline, 6 weeks, and 12 weeks. Diagnosis of hyperemia 
was in the investigator’s clinical judgment.
statistical methods
Unless otherwise specified, analyses were by intention to 
treat (ITT), and included all patients who were randomized. 
For ITT analyses, missing values of IOP were imputed using 
the method of last observation carried forward (LOCF): data 
from a patient’s last observed visit were carried forward in 
the analysis to the same hour of the subsequent visit. All 
secondary endpoint efficacy analyses were by ITT only.
The primary efficacy endpoint was analyzed by ITT, but 
also per protocol (PP) for confirmation purposes; these analy-
ses included all patients who were randomized, received at 
least one dose of study medication, had at least one follow-up 
visit, and who did not fulfill any of a predefined list of pro-
tocol violation criteria. PP analyses were based on observed 
cases only, with no missing values imputed.
Baseline and safety analyses included all patients who 
were randomized and treated with at least one dose of study 
medication.
Treatment groups were compared using analysis of cova-
riance (ANCOVA) with pooled investigator site as a factor 
for continuous variables, or the Cochran–Mantel–Haenszel 
(CMH) test with stratification by pooled investigator site for 
categorical variables, unless otherwise stated. All analyses 
used SAS software (v9.1.3; SAS Institute, Cary, NC, USA). 
No power calculation was performed, as this was a pilot study, 
part of the function of which was to provide an estimate of 
effect for larger studies.
Results
A total of 81 patients were randomized, 43 to BTFC and 
38 to LM, and ITT analyses were based on this group. Of 
these, 13 were classified as major protocol violators, thus PP 
analyses were based on 68 patients. Table 1 shows the overall 
flow of patients through the study. Patients were enrolled 
from June 3, 2010 to February 14, 2012.
Baseline characteristics
Of the 81 patients enrolled, 43 (53.1%) were male and 
38 (46.9%) were female. Almost all were of Caucasian eth-
nicity (98.8%); the remainder were Afro-Caribbean. Their 
mean (SD) age was 64.6 years (12.0).
With regard to risk factors for progression, 23 (28.4%) 
had pseudoexfoliation, 27 (33.3%) a family history of glau-
coma, seven (8.6%) pigment dispersion, one (1.2%) optic 
disc hemorrhage, 35 (43.2%) a visual field mean deviation 
worse than −6 dB, and 45 (55.6%) an IOP $27 mmHg in 
both eyes. Some patients had more than one risk factor, hence 
the total exceeds 100%.
Overall IOP change from baseline
Analyzed by ITT, the primary endpoint of mean (SD) change 
in IOP from baseline to 12 weeks was significantly greater 
in the BTFC group than in the LM group: −13.5 mmHg 
(4.48) for BTFC versus (vs) −11.4 mmHg (3.19) for LM; 
least squares mean (LSM) difference −2.04 mmHg, 95% 
confidence interval (CI): −3.35 to −0.73, P=0.003 (Table 2). 
PP analyses gave similar results, with an LSM difference of 
−1.96 mmHg (95% CI: −3.46 to −0.46, P=0.011). Both ITT 
and PP analyses found no significant interaction between 
pooled site and this outcome, indicating that the effect of 
treatment did not differ between pooled sites. Individual 
results are shown as a scattergram in Figure 1.
IOP change from baseline by time of day
At 12 weeks, the secondary endpoint of mean (SD) changes 
from baseline IOP by time of day were: at 8 am, –14.6 mmHg 
(4.04) for BTFC vs –12.3 mmHg (3.64) for LM (P=0.006); at 
12 pm, –13.6 mmHg (5.50) for BTFC vs –11.8 mmHg (3.14) 
Table 1 Patient disposition
BTFC  
(n=43)
LM  
(n=38)
Total
enrolled 43 38 81
randomized (iTT analyses) 43 38 81
Per protocol analyses 35 33 68
safety analyses 43 39* 81
Completed study 42 38 80
Discontinued** 1 0 1
Notes: Data are numbers; *one subject received both study drugs; **due to a 
serious adverse event unrelated to study medication.
Abbreviations: BTFC, fixed combination of 0.03% bimatoprost and 0.5% timolol; 
iTT, intention to treat; lM, latanoprost monotherapy.
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for LM (P=0.008); and at 4 pm, −12.4 mmHg (5.16) for BTFC 
vs −10.3 mmHg (4.24) for LM (P=0.003). The difference 
between the two treatments was thus not greatly affected by 
time of day, being about 2 mmHg at all measured times.
attainment of iOP targets
At 12 weeks, the secondary endpoints of predefined pressure 
reductions were reached by significantly more patients in the 
BTFC group than in the LM group, for IOP reductions of 
at least 40% (74.4% vs 47.4%, P=0.015) and at least 50% 
(46.5% vs 15.8%, P=0.003); other differences were not 
statistically significant (Figure 2A).
Similarly, at 12 weeks, significantly more patients had 
attained notional IOP targets of #14, #15, and #16 mmHg 
in the BTFC group than in the LM group (P=0.001, 0.006, 
and 0.008, respectively), whereas differences with respect 
to higher and lower targets were not statistically significant 
(Figure 2B).
Differences from baseline in highest  
and lowest iOP recorded
At 12 weeks, the mean change from baseline for the highest 
and lowest IOP was greater in both respects for the BTFC 
group than for the LM group: highest IOP (mmHg) −15.3 
(SD 4.44) for BTFC vs −12.9 (3.82) for LM, P=0.007; 
lowest −11.8 (5.23) for BTFC vs −9.9 (3.71) for LM, 
P=0.007. The difference between BTFC and LM was again 
approximately 2 mmHg for both measurements, suggesting 
that the greater overall IOP reduction with BTFC is not asso-
ciated with greater variability in IOP, compared to LM.
Safety and tolerability
All 81 patients randomized also received at least one dose 
of medication, and were thus included in safety analyses; 
however, one patient received both BTFC (up to visit 3) and 
LM (thereafter) and was therefore counted in both treatment 
groups for the safety analyses.
adverse events
A total of 46 AEs were reported by 27 patients (33.3%) dur-
ing the study. More AEs were reported in the BTFC group 
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Figure 1 Individual IOPs at baseline and at 12 weeks for the BTFC (n=43) and lM 
(n=38) groups. 
Abbreviations: BTFC, fixed combination of 0.03% bimatoprost and 0.5% timolol; 
iOP, intraocular pressure; lM, latanoprost monotherapy.
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Figure 2 Proportions of patients achieving predefined IOP reductions at 12 weeks: 
(A) by percentage; (B) by absolute level. 
Note: asterisks indicate significant difference between groups (Cochran–Mantel–
haenszel test). 
Abbreviations: BTFC, fixed combination of 0.03% bimatoprost and 0.5% timolol; 
iOP, intraocular pressure; lM, latanoprost monotherapy.
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Table 2 Change in mean IOP between baseline and week 12 visit
BTFC  
(n=43)
LM  
(n=38)
P-value
Mean IOP at baseline (mmHg) 28.4 (3.35) 28.5 (2.57) nT
Mean iOP at week 12 (mmhg) 14.9 (3.08) 17.0 (2.95) nT
Change from baseline (mmHg) –13.5 (4.48) –11.4 (3.19) 0.003
Note: All data are means (SD); analysis by intention to treat.
Abbreviations: BTFC, fixed combination of 0.03% bimatoprost and 0.5% timolol; 
iOP, intraocular pressure; lM, latanoprost monotherapy; nT, not tested; sD, 
standard deviation.
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(33 events in 19 patients, 44.2% of the group) than in the LM 
group (13 events in eight patients, 20.5% of the group). The 
majority of AEs were mild in severity (28/46) and assessed 
as related to the study drug (30/46). Ocular hyperemia, 
blepharitis, conjunctival hyperemia, and eye irritation were 
the most frequently reported AEs in both treatment groups 
(Table 3).
At the last study visit, 27 AEs were ongoing (17 in the 
BTFC group and ten in the LM group), while 18 had resolved 
without sequelae (15 in the BTFC group and three in the LM 
group). Only one AE (colon cancer) resolved with sequelae 
(in the BTFC group), as detailed in the next paragraph.
Two patients in the BTFC group reported one severe AE 
each. The first was reduced visual acuity (from 20/20 pre-
study and at baseline to 20/40 at weeks 6 and 12), reported as 
ongoing at the last study visit; this was assessed as not related 
to the study drug, and was not considered a serious AE (SAE). 
The second was colon cancer, which was moderate at baseline 
and became severe in intensity during the study, leading to the 
patient’s withdrawal from the study; this was the only SAE 
reported during the study, resolved with sequelae, and was 
assessed as not related to the study drug. This was also the 
only patient who discontinued treatment because of adverse 
events. No deaths were reported during the study.
Discussion
While fixed combination treatments may have advantages 
over the same medications prescribed concurrently in terms 
of compliance, lack of washout, and reduced exposure to pre-
servatives, the current EGS guidelines recommend their use 
only when monotherapy has failed to achieve sufficient IOP 
reduction.1 The basis of this recommendation is essentially 
two-fold: the general principle of using the minimal thera-
peutic approach that is effective, and the specific tactical 
consideration that if a combination treatment is given to 
treatment-naïve patients and is poorly tolerated or not as 
effective as expected, it is sometimes difficult to be sure 
which component of the treatment is causing the problem.
However, if a patient appears to be at high risk of visual 
disability from glaucoma, it may be clinically justifiable to 
prescribe a fixed combination immediately for greater IOP 
lowering and more rapid disease control. The rationale for 
this is that by the time it becomes clinically apparent that 
monotherapy is not achieving sufficient disease control, the 
glaucoma damage may already have progressed significantly 
towards the onset of visual disability. Similarly, although 
there is a theoretical problem with poor tolerability, in 
practice, the common adverse effects of such treatments are 
mild, manageable, and well known based on long-term use, 
so long as expectations are correctly set, and patients are 
unlikely to discontinue provided the treatment is effective. 
The principal clinical factors prompting this approach are 
likely to be advanced glaucoma damage, very high IOP, or 
the presence of exfoliation.
In this group of treatment-naïve patients with POAG or 
pseudoexfoliative glaucoma at high risk of glaucomatous 
progression, BTFC and LM both lowered IOP effectively 
with an acceptable safety profile. These patients had quite 
wide variation in their risk factors for progression, making it 
unlikely that this result is specifically related to any one risk 
factor. However, while patients receiving BTFC and those 
receiving LM both reported IOP reductions at 12 weeks, 
greater overall IOP reductions were seen in patients receiv-
ing BTFC.
Table 3 Ocular adverse events reported during the study
Adverse event BTFC (n=43) LM (n=39) Total (n=81)
Patients (%) Events Patients (%) Events Patients (%) Events
all ocular adverse events 14 (32.6) 20 8 (20.5) 12 22 (27.2) 32
Ocular hyperemia 7 (16.3) 7 4 (10.3) 4 11 (13.6) 11
Blepharitis 1 (2.3) 1 2 (5.1) 2 3 (3.7) 3
Conjunctival hyperemia 1 (2.3) 1 2 (5.1) 2 3 (3.7) 3
eye irritation 2 (4.7) 2 1 (2.6) 1 3 (3.7) 3
Conjunctivitis 2 (4.7) 2 0 0 2 (2.5) 2
Foreign body sensation in eyes 0 0 2 (5.1) 2 2 (2.5) 2
Keratitis 2 (4.7) 2 0 0 2 (2.5) 2
lacrimation increased 1 (2.3) 1 1 (2.6) 1 2 (2.5) 2
Conjunctivitis allergic 1 (2.3) 1 0 0 1 (1.2) 1
eye pain 1 (2.3) 1 0 0 1 (1.2) 1
eye pruritus 1 (2.3) 1 0 0 1 (1.2) 1
Visual acuity reduced 1 (2.3) 1 0 0 1 (1.2) 1
Abbreviations: BTFC, fixed combination of 0.03% bimatoprost and 0.5% timolol; LM, latanoprost monotherapy.
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Few previous studies have specifically assessed the use of 
fixed-combination therapies in treatment-naïve patients with 
glaucoma or ocular hypertension, and only one has compared 
BTFC and LM in this clinical setting, to our knowledge.
A 2013 randomized, observer-masked study (Konstas 
et al) compared BTFC to LM as initial therapy in 41 patients 
with newly diagnosed, previously untreated exfoliation 
syndrome or exfoliative glaucoma, and baseline morning 
IOP .29 mmHg.10 Twenty-four-hour IOP was measured 
at baseline and at 3 and 6 months, with treatment groups 
crossed over at 3 months to the alternate therapy. Mean 
24-hour IOP was significantly lower with BTFC vs LM 
(18.9 vs 21.2 mmHg, P,0.001), and BTFC reduced IOP 
significantly more than latanoprost at every time point, for 
the mean peak and trough 24-hour IOP (P,0.001). While the 
Konstas study was wholly in patients with exfoliative disease 
(vs only 28.4% in the current study) and their baseline IOP 
was somewhat higher, the difference reported in mean IOP 
between treatments was quite similar (2.3 mmHg in Konstas 
et al vs 2.04 mmHg in this study).
A 2007 randomized, double-masked study (Hommer 
et al) compared BTFC with either an unfixed combination 
of bimatoprost and timolol, or bimatoprost monotherapy, in 
445 treatment-naïve patients with ocular hypertension or 
glaucoma and IOP of 24–34 mmHg.11 At 3 weeks, BTFC 
was non-inferior to the unfixed combination, reduced mean 
diurnal IOP by 8.8 mmHg from baseline, and was well toler-
ated, with fewer adverse events than the other two regimens. 
The smaller effect of BTFC on IOP in the Hommer study 
compared with the present data may reflect both the shorter 
study duration and the inclusion of patients with lower IOP 
(24–34 vs 27–34 mmHg).
A 2003 randomized study compared dorzolamide/timolol 
fixed combination (DTFC) with LM in 65 newly diagnosed 
patients with exfoliative glaucoma.12 At 2 months, among 
the 54 patients completing the study, IOP was reduced by 
13.1 mmHg in the DTFC group, and by 12.3 mmHg in the 
LM group. However, eight patients discontinued therapy 
because of lack of IOP control, implying that an analysis 
by ITT would yield lower results. It is also unclear how far 
results in exfoliative glaucoma patients, who usually also 
have very high IOP, can be applied to the general glaucoma 
population, although this subgroup is certainly at high risk 
of progression, as exfoliation may carry an increased risk of 
progression even beyond the high IOP that generally accom-
panies it. Only 28.4% of the patients in the present study had 
exfoliative glaucoma.
Similarly, a 2008 randomized study compared the effect 
of DTFC with LM in 27 newly diagnosed and previously 
untreated patients with POAG, using a crossover design 
of two 6-week periods. However, the effects reported were 
relatively small, with observed 24-hour IOP reductions of 
7.4 mmHg with DTFC vs 6.1 mmHg with LM (P,0.0001), 
perhaps partly because baseline IOP was relatively low at 
22.7 mmHg after washout.13
A small, uncontrolled 2009 study assessed the use of 
latanoprost/timolol fixed combination (LTFC) in 28 previ-
ously untreated glaucoma patients with IOP $30 mmHg 
(21 POAG, six pseudoexfoliative glaucoma, and one pig-
mentary glaucoma).14 At 1 month, IOP was reduced by 
14.6 mmHg, but from a higher baseline IOP than in this 
study and over a shorter time period.
A 2010 open-label, unmasked study assessed the effec-
tiveness of DTFC, both alone and in combination with latano-
prost, in 164 patients with untreated open-angle glaucoma or 
ocular hypertension.15 Over 12 weeks, DTFC lowered IOP 
by 12.2 mmHg, and DTFC plus latanoprost by 13.4 mmHg. 
By comparison, in the present study, BTFC lowered IOP by 
13.5 mmHg over the same time period, suggesting that BTFC 
may be more effective than DTFC in treatment-naïve patients, 
and perhaps as effective as DTFC plus latanoprost. However, 
the two studies had slightly different inclusion criteria (all 
patients in the present study had glaucoma) and the patient 
groups thus may not be directly comparable.
A larger effect of DTFC was reported in a small 
2005 open-label, unmasked study in 18 patients with 
IOP .30 mmHg (mean 37.5 mmHg) who had been untreated 
for 1 month, rather than being entirely treatment-naïve.16 At 
2 months, IOP reduction was reported as 19.9 mmHg at peak 
and 16.4 mmHg at trough, but the average baseline IOP was 
nearly 10 mmHg higher than in this study.
A long-term, open-label, unmasked 2010 study compared 
DTFC with LTFC in 178 previously untreated patients.17 
Over 4 years, DTFC lowered IOP by 8.8 mmHg, and LTFC 
by 7.6 mmHg, with some evidence of reduced glaucomatous 
progression in the DTFC group. Given the different time 
frame, it is difficult to assess how these results compare 
with those of the present study, but clearly fixed combina-
tion treatment is a reasonable option in patients at sufficient 
risk of progression.
Despite some variation in the findings, all these studies 
suggest that treatment with a fixed combination is generally 
well tolerated and effective in treatment-naïve patients, with 
no serious safety concerns. Similarly, the present study also 
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reveals no new safety concerns for BTFC, with the adverse 
events reported consistent with those observed in previous 
studies. Both treatments were generally well tolerated, with 
only one discontinuation during the study, adjudged not 
related to study treatment. The incidence of ocular hyper-
emia was comparable between drugs (18.6% of patients with 
BTFC vs 15.4% with LM), consistent with existing evidence 
that adding timolol to bimatoprost reduces the likelihood of 
this effect.18
In conclusion, BTFC appears to be effective and well 
tolerated in treatment-naïve patients with POAG or pseudo-
exfoliative glaucoma who are at high risk of progression, in 
line with the existing data supporting its use in patients who 
are insufficiently responsive to monotherapy.
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